Antibiotic resistance is a massive problem and it's come about from the fact that microbes respond to pressure and genetic selection and if you keep pressing on them with an antibiotic, they'll become resistant to it. It's often rather easy for bacteria to find a way around. That’s very difficult for that to happen with HOCl. So HOCl has a place in hospital-acquired infection control. 

 

And by the way, a lot of those infectious organisms are brought into the hospital and people who are carriers. They carry some of those antibiotic-resistant organisms on their skin, up their nose, in their mouth. So, there is a seeding process that goes on in hospital acquired infection generation.

 

HOCl definitely has a place there, as there really is no solid evidence of HOCl resistance found. That just doesn't happen with HOCl. So, I think there's a really important role for HOCl in the future as an important tool in resisting and controlling hospital acquired infections and in particular those that are multi-drug resistant.
 

-- Jeffrey F. Williams, PhD, BVSc, MRCVS, microbiologist and infectious disease expert, has devoted his career to researching, inventing and bringing to market solutions that have improved the lives and health of people all over the world. 

 

-- Professor of Microbiology and Molecular Genetics, Michigan State University (Emeritus)

 

-- Elected Fellow of the American Association for the Advancement of Science (AAAS)

 

-- Holder of 30+ patents covering water treatment, disease control, odor control

 

-- Author of 200+ scientific papers and textbook chapters

 

-- Member of the Board of Counselors, National Institute of Allergy and Infectious Diseases, National Institute of Health (1984-88)

 

-- ​Chairman of a World Health Organization research committee on tropical diseases (based in Geneva) (1985-1989)

 

-- Chief Science Officer, HOCL producer that is world leader in hypochlorous acid technology and manufacturing (2014-2024)